Skip to content
Screener

IDEAYA Biosciences, Inc. IDYA Q4 2025 Annual earnings

Reported February 17, 2026 · Before market open

Revenue$10.9MBeat by $4.6M
EPS-$0.94Beat by $0.01
Revenue estimate$6.3M
EPS estimate-$0.95

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$6.8M
EPS estimate-$1.18

Financials

Q4 2025

Income statement

See full
Revenue$10.9M+55.4%
Operating income-$94.6M+34.4%
Net income-$83.3M+36.1%
EPS (diluted)-$0.94+39.4%

Balance sheet

See full
Cash & equivalents$112.8M+33.7%
Total debt$27.9M+45.6%
Total equity$1.0B-3.4%
Total assets$1.1B-1.3%

Cash flow

See full
Operating cash flow-$90.5M+25.6%
CapEx$333.0K-69.8%
Free cash flow-$90.8M+26.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.03B+36.4%
Enterprise value$2.95B+36.6%

Returns & leverage

See full
Return on equity-10.9%-4.4pp
Debt / equity0×0.0×
Current ratio11.3×-3.6×

FAQ

When did IDEAYA Biosciences, Inc. report Q4 2025 earnings?
IDEAYA Biosciences, Inc. (IDYA) reported Q4 2025 earnings on February 17, 2026 before market open.
What were IDEAYA Biosciences, Inc.'s Q4 2025 revenue and EPS?
IDEAYA Biosciences, Inc. reported revenue of $10.9M and eps of $-0.94 for Q4 2025.
Did IDEAYA Biosciences, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $6.3M by $4.6M. EPS beat the consensus estimate of $-0.95 by $0.01.
How did IDEAYA Biosciences, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 55.4% from $7.0M a year earlier and eps grew 36.9% from $-1.49.
Where can I find IDEAYA Biosciences, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-052741) and the 10-K periodic report (0001193125-26-054533) directly on SEC EDGAR. The filing index links above go to sec.gov.